GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
637
c/trialwatch·posted 2 years ago by u/adaeze_weiss

9 months in and SURMOUNT is still the thing I get wrong

Readout Clean Column ×5

STEP. That is the whole post, but I will justify it.

Everything else people worry about in c/orforglipron is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does.

I say this having got it wrong for 9 months. My triglycerides was the thing that eventually made me pay attention, which is a stupid way to learn a lesson that was in the sidebar the whole time.

5,656 up / 5,019 down53% upvoted13 commentsid 30flfw28 Feb 2024

13 comments

7 in this archive, depth 2

best — the order this archive was captured in

u/rania_salinas84 points·2 years ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/nikhil_lindqvist58 points·2 years ago

Phase 2 or phase 3?

replysharereportpermalink
u/renal_outcomes_rnephro-curious23 points·2 years ago

off-label use data is different from approved-indication data

replysharereportpermalink
u/forest_plot_fionastats56 points·2 years ago

the 19 week readout is different from the 8 week readout

replysharereportpermalink
u/hazard_ratio_halstats48 points·2 years ago

SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/anders_karlsen39 points·2 years ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/injection_site_iris15 points·2 years ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →